Novo’s Wegovy pill is selling fast—and still stings

The pill everybody’s watching

Novo Nordisk says its Wegovy pill isn’t just getting attention — it’s getting the kind of take-up that makes pharma folks start refreshing the charts every 10 minutes. On Wednesday, the company said the launch has been the fastest in weight-loss drug history, which is pretty wild for a treatment that used to live mostly in “promising pipeline” slides.

Better guidance, same bruises

Here’s the catch: Novo only narrowly improved its financial guidance for the year. So yes, the pill is moving like hot cakes at a post-New Year’s gym, but the company still expects profit and sales to fall in 2026.

For investors, that means the story is still a tug-of-war:

• The Wegovy pill is clearly a demand engine.
• Novo is getting a little more optimistic about the year.
• But the broader financial picture is still under pressure.

Why this matters for your portfolio

This is the kind of update that can keep a stock bouncing around like a group chat after a surprise Fed headline. Strong launch momentum is nice, but markets usually want to know whether that momentum can turn into cleaner growth, better margins, and less hand-wringing about the rest of the business.

Big picture: Novo has a hit on its hands, but it’s still trying to prove that hit can rescue the whole year.